HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recombinant activated factor VII in cardiac surgery: single-center experience.

AbstractBACKGROUND:
The widespread off-label use of recombinant activated factor VII for the control of refractory postoperative hemorrhage continues despite a warning from the Food and Drug Administration. Although effective in reducing the need for transfusion of blood and blood products, safety concerns still prevail.
OBJECTIVE:
To compare the dosing and efficacy of recombinant activated factor VII between pediatric and adult patients, and in the operating room and intensive care unit.
METHODS:
The records of 69 patients (33 children and 36 adults) who underwent cardiovascular surgery and received recombinant activated factor VII were reviewed retrospectively. The dose of recombinant activated factor VII, mediastinal drainage, use of blood and blood products, incidence of thrombosis, and 28-day mortality were studied.
RESULTS:
the efficacy of recombinant activated factor VII was comparable in adults and children, despite the lower dose in adults. Prophylactic use of recombinant activated factor VII decreased the incidence of mediastinal exploration and the duration of intensive care unit stay. A 4.3% incidence of thrombotic complications was observed in this study.
CONCLUSION:
The efficacious dose of recombinant activated factor VII is much less in adults compared to children. Prophylactic use of recombinant activated factor VII decreases the dose required, the incidence of mediastinal exploration, and intensive care unit stay, with no survival benefit.
AuthorsSarvesh Pal Singh, Sandeep Chauhan, Minati Choudhury, Vishwas Malik, Shiv Kumar Choudhary
JournalAsian cardiovascular & thoracic annals (Asian Cardiovasc Thorac Ann) Vol. 22 Issue 2 Pg. 148-54 (Feb 2014) ISSN: 1816-5370 [Electronic] England
PMID24585784 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Hemostatics
  • Recombinant Proteins
  • recombinant FVIIa
  • Factor VIIa
Topics
  • Adolescent
  • Adult
  • Age Factors
  • Cardiac Surgical Procedures (adverse effects, mortality)
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Drug Dosage Calculations
  • Factor VIIa (administration & dosage, adverse effects)
  • Female
  • Hemostatics (administration & dosage, adverse effects)
  • Humans
  • India
  • Intensive Care Units
  • Length of Stay
  • Male
  • Middle Aged
  • Operating Rooms
  • Postoperative Hemorrhage (diagnosis, drug therapy, etiology, mortality)
  • Recombinant Proteins (administration & dosage, adverse effects)
  • Reoperation
  • Retrospective Studies
  • Thrombosis (chemically induced, therapy)
  • Time Factors
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: